Current development and limitations of chemotherapy and immunotherapy in triple-negative breast cancer

Jingxi Lai

doi:10.1117/12.2669663

24 March 2023 Current development and limitations of chemotherapy and immunotherapy in triple-negative breast cancer

Jingxi Lai

Author Affiliations +

Proceedings Volume 12611, Second International Conference on Biological Engineering and Medical Science (ICBioMed 2022); 1261132 (2023) https://doi.org/10.1117/12.2669663
Event: International Conference on Biological Engineering and Medical Science (ICBioMed2022), 2022, Oxford, United Kingdom

Abstract

Triple-negative breast cancer (TNBC) is known as an aggressive breast cancer subtype. Because of the lack of hormone receptors, there are a limited number of effective therapies, and relapse and migration of tumours are frequent after tumour treatment. New treatments and enhanced medical outcomes are urgently needed. Following prior research, chemotherapy is an established worldwide treatment with a favourable clinical outcome, whereas immunotherapy is emerging as a new area of study. The principal goal of this study is to examine and evaluate treatment procedures, treatment responses, and adverse effects related to these two medicines. Specifically, the research limitations that inhibit the accessibility and efficacy of each therapy are taken into consideration. Both treatments are successful for a subset of patients, as evidenced by data of pathological complete response (pCR) and median overall survival (OS), with side effects including chemoresistance and unstable biomarkers. Future directions for research and potential side effect solutions are discussed. Based on the studies, future research should concentrate on overcoming chemoresistance, identifying stable biomarkers, managing the tumour microenvironment (TME) for CAR T cell applications, and so on. This fruitful work exposes the current state of TNBC treatment and research perspectives. It encourages the development and improvement of TNBC therapeutic strategies by enhancing our understanding of both existing and potential therapies across various perspectives.

Citation Download Citation

Jingxi Lai "Current development and limitations of chemotherapy and immunotherapy in triple-negative breast cancer", Proc. SPIE 12611, Second International Conference on Biological Engineering and Medical Science (ICBioMed 2022), 1261132 (24 March 2023); https://doi.org/10.1117/12.2669663

ACCESS THE FULL ARTICLE

INSTITUTIONAL
Select your institution to access the SPIE Digital Library.

SELECT YOUR INSTITUTION

PERSONAL
Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.

PERSONAL SIGN IN

No SPIE Account? Create one

;

PURCHASE THIS CONTENT

SUBSCRIBE TO DIGITAL LIBRARY

50 downloads per 1-year subscription

Members: $195

Non-members: $335 ADD TO CART

25 downloads per 1 - year subscription

Members: $145

Non-members: $250 ADD TO CART

PURCHASE SINGLE ARTICLE